What is the difference between an anti-acne drug and an anti-blemish cosmetic?

An anti-acne drug contains pharmaceutical active ingredients (such as benzoyl peroxide, adapalene, or oral isotretinoin) designed to cure acne pathology, requiring clinical drug authorization. An anti-blemish cosmetic acts on the superficial epidermis to cleanse, absorb excess sebum, exfoliate dead surface cells, and visually minimize the appearance of skin imperfections.

Is a non-comedogenic test required to claim "does not clog pores"?

Yes. Under Commission Regulation (EU) No 655/2013 on cosmetic claims, declaring 'non-comedogenic' or 'does not clog pores' requires empirical proof. The laboratory conducts clinical comedogenicity scoring on volunteer panels with acne-prone skin under dermatological evaluation over 28 consecutive days.

Can natural willow bark extract replace synthetic salicylic acid?

Yes. Willow bark extract (INCI: Salix Alba Bark Extract) naturally contains salicin, which can be standardized to deliver natural salicylates. However, the exact concentration of active salicylic acid must still be quantified and verified to ensure it remains below the 2.0% legal limit in the finished product.

Blemish-Prone Skin Care: Formulation, Legal Claims & PIF

Blemish-Prone Skin Care: Natural Formulation Secrets, Borderline Claims, and PIF Compliance

Blemish-prone and acne-prone skin represents one of the largest, most emotionally resonant categories in the modern skincare industry. Millions of adolescents and adults actively seek natural, gentle botanical solutions to rebalance oily skin, unclog pores, and reduce the appearance of imperfections. While potent botanical actives - such as tea tree essential oil, zinc PCA, niacinamide, and natural salicylic acid - demonstrate remarkable cosmetic efficacy, commercializing these formulas in Europe requires navigating a strict legal borderline. Under European law, claiming to 'cure acne' reclassifies a cosmetic into an illegal unapproved drug. Here is our complete regulatory guide to formulating, testing, and marketing compliant blemish care under Regulation (EC) No 1223/2009.

💡 Formulating a purifying serum, anti-blemish lotion, or clarifying botanical face oil? Ensure the regulatory compliance of your active claims. Estimate your costs in 2 minutes with our configurator.

Launch the Configurator →

Understanding Blemish Physiology to Formulate Compliant Botanical Care

Blemish formation stems from four interrelated biological factors: hyperseborrhea (excess sebum production), follicular hyperkeratinization (pore clogging), proliferation of Cutibacterium acnes, and local inflammation. Compliant cosmetic formulations address these mechanisms through physiological balancing rather than pharmacological intervention:

Sebum-regulating actives: Zinc PCA (INCI: Zinc PCA) and Niacinamide (Vitamin B3) regulate surface shine and reduce excessive sebum secretion without stripping the epidermal moisture barrier.
Keratolytic and pore-clearing agents: Salicylic acid (BHA) or plant-derived wintergreen extracts loosen compacted cellular debris within the pilosebaceous follicle.
Purifying botanicals: Tea tree essential oil (Melaleuca Alternifolia), propolis, and rosemary extracts provide natural antimicrobial protection. However, essential oil concentrations must be strictly controlled to prevent irritation.

The blemish care PIF consolidates formulation records, safety assessments, and stability findings. To explore complementary facial skincare ranges, review our guide on face serum regulation, our dossier on the face care PIF, and our reference pillar on facial hygiene care regulation.

🔬 Cosmetic Safety Assessor Insights

"The legal boundary between cosmetics and pharmaceuticals is exceptionally sensitive in blemish skincare. The moment packaging claims a therapeutic effect - such as 'treats acne', 'cures infected pimples', or 'eliminates cystic blemishes' - the product is classified as a medicinal drug by regulatory surveillance authorities. In Part B of the CPSR, our qualified Safety Assessor verifies that all marketing claims, labeling texts, and active concentrations remain strictly within the cosmetic framework, substantiating that the formula purifies the skin surface, regulates excess sebum, and improves skin appearance without modifying physiological pathology."

Formulating Legally Marketable Anti-Blemish Cosmetics

To market your natural blemish care product legally in France, the European Union, or Switzerland, follow these mandatory milestones:

Adherence to Annex III active ingredient limits: Salicylic acid is capped at a strict 2.0% maximum in leave-on cosmetic products. Formulations exceeding 2% cannot be certified.
Stability and container compatibility testing: Accelerated aging tests at 40°C for 8 to 12 weeks to ensure emulsion or serum stability and compatibility with packaging materials (dropper bottles or airless pumps).
Microbiological challenge testing: Mandatory under ISO 11930 for aqueous serums and lotions to demonstrate preservative efficacy against microbial contamination.
Clinical dermatological testing: Human patch testing and non-comedogenicity testing under dermatological control on blemish-prone volunteer panels.
CPNP notification: Mandatory registration on the European Cosmetic Product Notification Portal before commercial launch.

⚠️ 3 Critical Errors in Natural Blemish Skincare Compliance

Making pharmaceutical therapeutic claims: Stating that your product 'cures acne' or 'eliminates bacterial infection' reclassifies your product into an illegal medicinal drug without Marketing Authorization (MA). Keep claims cosmetic ('purifies blemish-prone skin', 'visibly reduces the appearance of imperfections').
Overdosing tea tree essential oil: Utilizing undiluted or high percentages of tea tree oil (> 1-2%) causes contact sensitization, burning, and immediate refusal of the CPSR by the Safety Assessor.
Omitting fragrance allergens in the INCI list: Botanical essential oils naturally contain regulated allergens (limonene, linalool) that must be listed whenever exceeding 0.001% in leave-on cosmetics.

Botanical active ingredients and clinical skincare testing

Raw Material Compliance and Essential Oil Documentation

Formulating natural skincare requires rigorous raw material qualification. Explore our dedicated guide on cosmetic ingredients to understand the documentation trio (REACH 16-section SDS, TDS, and CoA) required for every botanical extract.

Frequently Asked Questions About Blemish Skincare Regulations

What is the difference between an anti-acne drug and an anti-blemish cosmetic?: An anti-acne drug contains pharmaceutical active ingredients (such as benzoyl peroxide, adapalene, or oral isotretinoin) designed to cure acne pathology, requiring clinical drug authorization. An anti-blemish cosmetic acts on the superficial epidermis to cleanse, absorb excess sebum, exfoliate dead surface cells, and visually minimize the appearance of skin imperfections.
Is a non-comedogenic test required to claim "does not clog pores"?: Yes. Under Commission Regulation (EU) No 655/2013 on cosmetic claims, declaring 'non-comedogenic' or 'does not clog pores' requires empirical proof. The laboratory conducts clinical comedogenicity scoring on volunteer panels with acne-prone skin under dermatological evaluation over 28 consecutive days.
Can natural willow bark extract replace synthetic salicylic acid?: Yes. Willow bark extract (INCI: Salix Alba Bark Extract) naturally contains salicin, which can be standardized to deliver natural salicylates. However, the exact concentration of active salicylic acid must still be quantified and verified to ensure it remains below the 2.0% legal limit in the finished product.